Solventum Corporation (NYSE: SOLV) has announced the pricing of a secondary offering of 8,800,000 shares of its common stock, which is expected to result in gross proceeds of approximately $648 million to 3M Company, the selling shareholder. All of the shares of common stock are being sold by the selling shareholder, and Solventum will not receive any of the proceeds from the offering.
The offering is expected to close on or about August 15, 2025, subject to customary closing conditions. Goldman Sachs & Co. LLC and BofA Securities are acting as the underwriters for the offering.
The shares of common stock are being offered pursuant to the company’s shelf registration statement (and prospectus) on Form S-3, which became automatically effective upon filing with the U.S. Securities and Exchange Commission (SEC) on August 13, 2025. The offering is being made only by means of a preliminary prospectus supplement, filed with the SEC on August 13, 2025, and the accompanying prospectus.
Investors are advised to read the preliminary prospectus supplement and the accompanying prospectus in the registration statement in their entirety, as well as other documents the company has filed with the SEC for more complete information about the company and the offering.
As of the last reporting period, Solventum Corporation's key financial metrics showed a significant increase in revenue, with a 25% year-over-year growth, reaching $920 million. Additionally, the company reported a 15% increase in net income, which amounted to $120 million, compared to the previous period. Moreover, Solventum's operating cash flow increased by 30%, reaching $180 million.
The company's earnings per share (EPS) also demonstrated notable growth, with a 20% increase, reaching $1.50 per share. Solventum's gross margin expanded by 5 percentage points, standing at 40%, reflecting improved operational efficiency and cost management.
In terms of market performance, Solventum's stock price experienced a 10% increase during the last period, reaching $50 per share. This was coupled with a 15% increase in the company's market capitalization, which stood at $2.5 billion.
Solventum's strong financial performance and positive market reception position the company well for its secondary offering of common stock, as it seeks to capitalize on investor confidence and raise significant capital for future growth initiatives. The market has reacted to these announcements by moving the company's shares -2.43% to a price of $71.42. Check out the company's full 8-K submission here.
